What did Evercore ISI do in the February 27, 2026 note for INSP?

Evercore ISI maintained an Outperform on Inspire Medical Systems on February 27, 2026 and highlighted that 3 of the 6 new CMS HCPCS codes are relevant for INSP analyst rating and future reimbursement clarity.

How did the market react to the INSP analyst rating update?

The stock moved **5.59% ($3.6)** after the note, reflecting investor approval of coding clarity and the maintained INSP analyst rating as supportive for procedure adoption and revenue.

Does the Evercore note include a new price target for INSP?

The cited Evercore note did not publish a new INSP price target. The firm maintained Outperform but did not change the publicly referenced price target in the StreetInsider summary.

What does Meyka AI’s grade mean for INSP investors?

Meyka AI rates INSP with a grade of A, based on S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. This complements the INSP analyst rating but is not financial advice.

Analyst Ratings

Evercore ISI Maintains Outperform on INSP (Inspire Medical Systems) Feb 2026

ByDanny Kontos February 28, 2026February 28, 2026

Evercore ISI maintained an Outperform on Inspire Medical Systems, Inc. (INSP) on February 27, 2026, citing that 3 of the 6 new HCPCS codes announced by CMS are relevant for the company. The INSP analyst rating note highlights coding clarity for hypoglossal nerve stimulation devices and keeps Evercore’s constructive stance. Investors should note the stock moved 5.59% ($3.6) since the report and that price detail at note time was not provided.